Christopher Davies

Christopher Davies is a skilled scientist with extensive experience in molecular biology and therapeutic development. Currently serving as a Scientist II at Beacon Therapeutics since July 2024, Christopher previously held the position of Principal Scientist at Evox Therapeutics Ltd from May 2019 to April 2024, leading a team in the innovation of a new therapeutic class by encapsulating AAV capsids within exosomes. Earlier roles include Postdoctoral Researcher at Queen Mary University of London, where research focused on von Willebrand Factor release mechanisms, and Sales Engineer at Hamamatsu, enhancing communication and presentation skills. Christopher earned a PhD in Molecular Biology from the University of Nottingham, along with a Biochemistry degree from the University of Warwick.